retatrutide ly3437943 glp-1 gip glucagon LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Structural insights into the triple

Prescription required, subject to provider review

Cons of Lifestyle Programs: Modest weight loss results and high dependence on personal discipline

As the image below shows, fat consumption has steadily risen over the last century since we discovered how to extract oil from crops at scale, fuelled by synthetic fertilisers

Mar 25, 2026 What happens if your injection day falls on the worst possible day this week

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, currently in clinical development for obesity and type 2 diabetes

Above these thresholds, uptake stays confined to high-income percentiles despite strong demand signals